Cerity Partners’s Sarepta Therapeutics SRPT Stock Holding History

Cerity Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Sell	72,728 -77,122	-51%	-$1.46M	﹤0.01%	1829
2026 Q1	$3.26M	Sell	149,850 -62,466	-29%	-$1.21M	﹤0.01%	1217
2025 Q4	$4.57M	Buy	212,316 +174,187	+457%	+$3.67M	0.01%	960
2025 Q3	$735K	Buy	+38,129	New	+$680K	﹤0.01%	1752
2025 Q1	–	Sell	-2,741	Closed	-$339K	–	2619
2024 Q4	$339K	Sell	2,741 -538	-16%	-$65.9K	﹤0.01%	1970
2024 Q3	$410K	Buy	3,279 +1,166	+55%	+$161K	﹤0.01%	1889
2024 Q2	$334K	Buy	2,113 +401	+23%	+$51.5K	﹤0.01%	1763
2024 Q1	$222K	Buy	+1,712	New	+$210K	﹤0.01%	2052

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cerity Partners's SRPT Position: Q2 2026 in Review

Cerity Partners reduced its Sarepta Therapeutics (SRPT) stake by 51% in Q2 2026, selling an estimated $1.46M and leaving 72,728 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Cerity Partners first reported a position in SRPT in Q1 2024 and has held it in 8 quarters since. The position peaked at $4.57M in Q4 2025. 298 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Cerity Partners held 72,728 shares of Sarepta Therapeutics worth $1.31M as of Q2 2026.
Cerity Partners sold 77,122 Sarepta Therapeutics shares in Q2 2026, an estimated $1.46M.
Sarepta Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1829 holding.
Cerity Partners first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 8 quarters since.
Cerity Partners's Sarepta Therapeutics position peaked at $4.57M in Q4 2025.
298 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.